Our first-in-class lead program, STAR0602, is a bispecific antibody fusion molecule which utilizes our STAR platform approach to bind and activate a specific Vβ T cell subset, while also delivering a costimulatory signal to the same T cell (known as cis-targeting). Using this approach, STAR0602 further “tunes” the activation and differentiation of Vβ T cells for enhanced anti-tumor activity and durability.
Marengo’s antibodies are being studied for use as monotherapies in initial development programs because of their profound single agent activity in preclinical models. We intend to explore potential combinations with a range of IO and standard-of-care treatments.
Subsequent follow on STAR programs will capitalize on validated but orthogonal T cell co-stimulators and targeting arms to expand treatments across a broad range of solid tumors.
To continue to maximize opportunities, particularly in cold tumors, Marengo is also advancing platforms that activate other types of immune cells.